INmune Bio to Present Positive Phase 2 Imaging Data for XPro in Early Alzheimer’s Disease at AAIC
INmune Bio reported positive Phase 2 imaging data for XPro1595 in early Alzheimer’s disease, showing statistically significant treatment-related changes in white matter myelin integrity at Week 24 (p < 0.01). The data, to be presented at the AAIC 2026 conference, also showed concordant effects in cortical gray matter microstructure using independent MRI methods, supporting the drug’s engagement with relevant biology.
Key figures
- Drug Name
- XPro1595
- Phase Of Trial
- Phase 2
- Timepoint
- Week 24
- P value white matter
- < 0.01
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.